Search results for "lymphoma."

showing 10 items of 697 documents

B-MIND: MOR208 plus bendamustine (BEN) versus rituximab (RTX) plus BEN in patients with relapsed or refractory (R-R) diffuse large B-cell lymphoma (D…

2017

TPS7571 Background: Patients ineligible for stem cell transplantation (SCT) or who relapse after SCT, and those who fail to respond to second-line or salvage chemotherapy, represent an unmet medical need for which new therapeutic strategies are required. MOR208 is a novel Fc-enhanced, humanized, monoclonal antibody directed against CD19. Significant single-agent activity of MOR208 in patients with R-R DLBCL (Jurczak et al., J Clin Oncol 34, 2016 [suppl; abstr 7545]) and enhancement of MOR208-mediated cytotoxicity by BEN in preclinical studies, provide a strong rationale to study MOR208 + BEN in patients with R-R DLBCL. Methods: B-MIND is a randomized (1:1), two-arm, multicenter, open-label…

0301 basic medicinePHASE II/III TRIALOncologyBendamustineCancer Researchmedicine.medical_specialtybusiness.industrymedicine.diseaseSurgeryTransplantation03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyRefractory030220 oncology & carcinogenesisInternal medicinemedicineRituximabIn patientStem cellbusinessDiffuse large B-cell lymphomamedicine.drugJournal of Clinical Oncology
researchProduct

Histologic transformation to diffuse large B cell lymphoma with profuse signet-ring cell change in bone marrow and lymph node biopsies in a patient w…

2016

0301 basic medicinePathologymedicine.medical_specialtyHistologySignet ring cellbusiness.industryGeneral Medicinemedicine.diseasePathology and Forensic Medicine03 medical and health sciencesTransformation (genetics)030104 developmental biology0302 clinical medicinemedicine.anatomical_structure030220 oncology & carcinogenesisCytologymedicineBone marrowDifferential diagnosisbusinessLymph nodeDiffuse large B-cell lymphomaHistological correlationDiagnostic Cytopathology
researchProduct

Plasmablastic lymphoma as a manifestation of the human immunodeficiency virus: Case report

2020

Plasmablastic lymphoma is a rare subtype of non-Hodgkin’s lymphoma, which generally presents an aggressive clinical course and low survival rates. It is strongly associated with HIV infection and the most common site of involvement of the territory of the head and neck is Waldeyer’s lymphatic ring, followed by the gastrointestinal tract, lymph nodes and skin. The morphological characteristics of PBL in the oral cavity / jaw in the context of HIV infection show diffuse sheets of large immunoblastic cells with abundant cytoplasm, vesicular chromatin and prominent nucleus, a small located in the center with plasma cells differentiation. The main goal of this article is to review the literature…

0301 basic medicinePathologymedicine.medical_specialtyHuman immunodeficiency virus (HIV)Case ReportContext (language use)medicine.disease_cause03 medical and health sciences0302 clinical medicineAcquired immunodeficiency syndrome (AIDS)immune system diseaseshemic and lymphatic diseasesmedicineGeneral DentistryGastrointestinal tractOral Medicine and Pathologybusiness.industry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseLymphoma030104 developmental biologyLymphatic system030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASLymphbusinessPlasmablastic lymphomaJournal of Clinical and Experimental Dentistry
researchProduct

Unusual presentation of blastic plasmacytoid dendritic cell neoplasm: Pitfalls in other hematolymphoid neoplasms

2020

Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare CD4+/CD56+ hematological malignancy with aggressive clinical course and poor prognosis. Histologically, BPDCN is characterized by a diffuse, monomorphous infiltration of cutaneous, subcutaneous, and sometimes other tissues such as lymph nodes and bone marrow, by medium-sized neoplastic cells with blastoid morphology. Typically, there is absence of lymphocytic infiltrate. Diagnosis relies on immunophenotypic expression of CD4, CD56, and the more specific markers of plasmacytoid dendritic cells CD123, CD303/BDCA2, and TCL1. We report a case of a 57-year-old man who presented a 4 cm-long solitary, erythemateous lesion on t…

0301 basic medicinePathologymedicine.medical_specialtyMyeloidMYCASXL1BlastoidPathology and Forensic MedicineLymphocytic Infiltrate03 medical and health sciences0302 clinical medicineBlastic plasmacytoid dendritic cell neoplasmT-cells infiltrationlcsh:PathologyMedicineTET2biologybusiness.industryETV6medicine.diseasebiology.organism_classificationLymphomaETV6030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisInterleukin-3 receptorBone marrowbusinessInfiltration (medical)lcsh:RB1-214Human Pathology: Case Reports
researchProduct

Changes in life expectancy for cancer patients over time since diagnosis

2019

Highlights • Research question: how cancer impacts on LE changes during patients’ entire life • LE increased in patients surviving the first years and decreasing thereafter. • Patients’ LE in the end approached but seldom reached the general population’s LE. • This method describes when cancer survivors’ excess risk of death became negligible. • Life expectancy indicator is easy to be understood and interpreted by patients.

0301 basic medicinePediatricsmedicine.medical_specialtycancer survivorLife expectancyCancer survivorsPopulationYLL years of life lost(ICD-O-3) international classification of diseases for oncology third revisionSocio-culturaleLife expectancy Population-based cancer registry Relative survival Cancer Cancer survivors ItalySettore MED/42 - Igiene Generale E ApplicataRelative survival03 medical and health sciences0302 clinical medicineHealth careMedicineeducationlcsh:Science (General)Population-based cancer registryThyroid cancerCancerRS relative survivaleducation.field_of_studylcsh:R5-920MultidisciplinaryRelative survivalbusiness.industryAbsolute risk reductionCancermedicine.diseaseLE life expectancyNHL non-Hodgkin lymphoma030104 developmental biologyYears of potential life lostItalyISTAT national institute of statistics030220 oncology & carcinogenesisLife expectancy(ICD-10) international classification of diseases tenth revisionOriginal Articlebusinesslcsh:Medicine (General)lcsh:Q1-390Journal of Advanced Research
researchProduct

Mathematical model of T-cell lymphoblastic lymphoma: disease, treatment, cure or relapse of a virtual cohort of patients

2017

International audience; T lymphoblastic lymphoma (T-LBL) is a rare type of lymphoma with a good prognosis with a remission rate of 85%. Patients can be completely cured or can relapse during or after a 2-year treatment. Relapses usually occur early after the remission of the acute phase. The median time of relapse is equal to 1 year, after the occurrence of complete remission (range 0.2–5.9 years) (Uyttebroeck et al., 2008). It can be assumed that patients may be treated longer than necessary with undue toxicity. The aim of our model was to investigate whether the duration of the maintenance therapy could be reduced without increasing the risk of relapses and to determine the minimum treatm…

0301 basic medicinePediatricsmedicine.medical_specialtymedicine.medical_treatmentPopulation[SDV.CAN]Life Sciences [q-bio]/CancerPrecursor T-Cell Lymphoblastic Leukemia-LymphomachemotherapyGeneral Biochemistry Genetics and Molecular Biology[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences[ MATH.MATH-AP ] Mathematics [math]/Analysis of PDEs [math.AP][SDV.CAN] Life Sciences [q-bio]/CancerMaintenance therapythymusT-cell lymphoblastic lymphomamedicineHumanscancer[MATH.MATH-AP]Mathematics [math]/Analysis of PDEs [math.AP]Computer Simulationmathematical modelling[MATH.MATH-AP] Mathematics [math]/Analysis of PDEs [math.AP]educationrandomized controlled clinical trialGeneral Environmental SciencePharmacologyChemotherapyeducation.field_of_studyGeneral Immunology and Microbiologybusiness.industryApplied MathematicsGeneral NeuroscienceLymphoblastic lymphomaCancerGeneral MedicineModels Theoreticalmedicine.disease3. Good healthLymphomaSurgeryClinical trial030104 developmental biologyModeling and SimulationCohortDisease ProgressionbusinessMathematical Medicine and Biology
researchProduct

Viral Bcl2s' transmembrane domain interact with host Bcl2 proteins to control cellular apoptosis

2020

© The Author(s) 2020.

0301 basic medicineProgrammed cell deathScienceProtein domainGeneral Physics and AstronomyApoptosisBiologyVirus-host interactionsArticleGeneral Biochemistry Genetics and Molecular BiologyFluorescenceCell Line03 medical and health sciences0302 clinical medicineProtein Domainsimmune system diseaseshemic and lymphatic diseasesmedicineHumansAmino Acid SequenceAuthor CorrectionPeptide sequenceneoplasmsMultidisciplinaryVirus–host interactionsQCell MembraneGeneral ChemistryViral proteinsmedicine.diseaseControl cellLymphomaCell biologyVirusTransmembrane domain030104 developmental biologyProto-Oncogene Proteins c-bcl-2Cell cultureApoptosisDoxorubicin030220 oncology & carcinogenesisbiological phenomena cell phenomena and immunityProtein MultimerizationHydrophobic and Hydrophilic InteractionsProteïnesProtein Binding
researchProduct

The C-terminal Domains of Apoptotic BH3-only Proteins Mediate Their Insertion into Distinct Biological Membranes

2016

Changes in the equilibrium of pro- and anti-apoptotic members of the B-cell lymphoma-2 (Bcl-2) protein family in the mitochondrial outer membrane (MOM) induce structural changes that commit cells to apoptosis. Bcl-2 homology-3 (BH3)-only proteins participate in this process by either activating pro-apoptotic effectors or inhibiting anti-apoptotic components and by promoting MOM permeabilization. The association of BH3-only proteins with MOMs is necessary for the activation and amplification of death signals; however, the nature of this association remains controversial, as these proteins lack a canonical transmembrane sequence. Here we used an in vitro expression system to study the inserti…

0301 basic medicineProtein familyCèl·lulesBiologyBiochemistryMitochondrial Proteins03 medical and health sciencesProtein DomainsMembranes (Biologia)Protein-fragment complementation assayMembrane BiologyMicrosomesProto-Oncogene ProteinsHumansMolecular BiologyAdaptor Proteins Signal TransducingGeneticsBcl-2-Like Protein 11030102 biochemistry & molecular biologyCell MembraneBcl-2 familyProteïnes de membranaMembrane ProteinsBiological membraneCell BiologyFusion proteinTransmembrane proteinCell biology030104 developmental biologyMembraneProto-Oncogene Proteins c-bcl-2Membrane proteinB-cell lymphoma 2 (Bcl-2) family BH3-only apoptosis membrane insertion membrane protein mitochondrial apoptosis transmembrane domainApoptosis Regulatory ProteinsHydrophobic and Hydrophilic InteractionsHeLa CellsJournal of Biological Chemistry
researchProduct

Different Within-Host Viral Evolution Dynamics in Severely Immunosuppressed Cases with Persistent SARS-CoV-2

2021

12 páginas, 2 figuras, 1 tabla.

0301 basic medicineQH301-705.5medicine.medical_treatment030106 microbiologyInmunologíaMedicine (miscellaneous)GenomicsSingle-nucleotide polymorphismDiseaseBiologyArticleGeneral Biochemistry Genetics and Molecular BiologyVirusdiversityPersistence03 medical and health sciencesmedicinegenomicsBiology (General)Evolutionary dynamicsimmunosuppressedDiversitySARS-CoV-2COVID-19ImmunosuppressionGenomicspersistencemedicine.diseaseVirologyviral viabilityLymphoma030104 developmental biologyImmunosuppressedViral evolutionViral viability
researchProduct

HUMAN T-LYMPHOTROPIC VIRUS 1 (HTLV-1) AND HUMAN T-LYMPHOTROPIC VIRUS 2 (HTLV-2): GEOGRAPHICAL RESEARCH TRENDS AND COLLABORATION NETWORKS (1989-2012)

2016

Publications are often used as a measure of research work success. Human T-lymphotropic virus (HTLV) type 1 and 2 are human retroviruses, which were discovered in the early 1980s, and it is estimated that 15-20 million people are infected worldwide. This article describes a bibliometric review and a coauthorship network analysis of literature on HTLV indexed in PubMed in a 24-year period. A total of 7,564 documents were retrieved, showing a decrease in the number of documents from 1996 to 2007. HTLV manuscripts were published in 1,074 journals. Japan and USA were the countries with the highest contribution in this field (61%) followed by France (8%). Production ranking changed when the numb…

0301 basic medicineResearch groupsBiomedical Researchlcsh:Arctic medicine. Tropical medicinelcsh:RC955-962030231 tropical medicinePopulationBibliometricsGlobal HealthGross domestic product03 medical and health sciences0302 clinical medicineHuman T-lymphotropic virus (HTLV)Global healthMedicineHumansCooperative BehaviorSocioeconomicseducationeducation.field_of_studyHuman T-lymphotropic virus 1biologyGeographybusiness.industryHuman T-lymphotropic virus 2Tropical spastic paraparesisGeneral Medicinebiology.organism_classificationHTLV-I InfectionsT cell leukemia/lymphoma030104 developmental biologyInfectious DiseasesGross national incomeBibliometricsHuman T-lymphotropic virus 1Human T-lymphotropic virus 2ImmunologyOriginal ArticlePeriodicals as TopicbusinessResearch collaboration
researchProduct